Brind.
  1. The FDA reviewed the Biologics License Application (BLA) for MOGENRY, a gene therapy, involving Nanoscope Therapeutics, Inc.

Christine Kay, MD, has been appointed as Director of Clinical Research at Nanoscope Therapeutics, Inc.

1 report, 1 independent Updated Sep 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Christine Kay, MD, has been appointed as Director of Clinical Research at Nanoscope Therapeutics, Inc.

Keep exploring

Part of

The FDA reviewed the Biologics License Application (BLA) for MOGENRY, a gene therapy, involving Nanoscope Therapeutics, Inc. All 1 developments

Coverage

Newest first; wire copies grouped